Skip to main content
. 2018 Apr 28;24(10):2266–2271. doi: 10.1093/ibd/izy132

FIGURE 3.

FIGURE 3.

Incremental gain in biochemical, endoscopic, and histologic remission rates in relation to serum infliximab trough concentrations during maintenance therapy in patients with CD. Increments of 5 μg/mL infliximab trough concentration were used to define the range of maximal increase in the rate of biochemical, endoscopic, or histological remission with any increase in drug concentration during maintenance therapy. P value: linear-by-linear association.